Zymeworks Inc., a clinical-stage biotechnology company headquartered in Middletown, United States, has recently made notable disclosures regarding the financial activities of its Chief Financial Officer, Kristin Stafford. The company, which operates within the Health Care sector and is listed on the Nasdaq, specializes in the discovery and development of multifunctional biotherapeutics aimed at treating cancer. Zymeworks serves the pharmaceutical industry in both Canada and the United States.
On April 7, 2026, Zymeworks filed a Form 4 with the Securities and Exchange Commission (SEC), detailing the exercise of stock options and the grant of restricted stock units by Kristin Stafford. This filing reveals that Stafford has acquired a significant number of common shares, encompassing both option and restricted-stock awards. The document outlines the vesting schedules associated with each type of award, providing transparency into the timeline of her ownership stake in the company.
Prior to this, on April 1, 2026, Zymeworks had filed a Form 3, indicating that Stafford held no beneficial ownership of securities at that time. The subsequent Form 4 filing marks a substantial change, showcasing Stafford’s acquisition of a considerable position in the company. Additionally, the filings include a power-of-attorney document, appointing legal counsel to manage the filing of required Forms ID, 3, 4, and 5 on Stafford’s behalf. This legal arrangement ensures compliance with SEC reporting requirements.
It is noteworthy that no other executives or directors have reported beneficial ownership in the recent filings. This development highlights Stafford’s evolving stake in Zymeworks and underscores the company’s commitment to transparency in its financial disclosures.
As of April 7, 2026, Zymeworks’ close price stood at $26.71, with a 52-week high of $28.49 recorded on November 25, 2025, and a 52-week low of $9.40 on April 10, 2025. The company’s market capitalization is valued at $1.92 billion, with a price-to-earnings ratio of -23.92, reflecting its current financial standing in the biotechnology sector.
These recent activities and disclosures by Zymeworks Inc. provide valuable insights into the company’s internal financial dynamics and the strategic positioning of its key executives. As Zymeworks continues to advance its clinical-stage biotherapeutics, the evolving ownership stakes of its leadership may play a pivotal role in shaping its future trajectory in the competitive landscape of cancer treatment innovation.
